CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines

After facing rebuke from FDA, CytoDyn Inc CYDY plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies, including those in India and the Philippines.
Patients in the CD12 trial were administered two doses of leronlimab; on day zero and day seven.
Results showed that critically ill patients receiving leronlimab on day zero experienced a mortality rate of 78% lower than patients receiving placebo over that initial span.
Further, patients receiving the second dose of leronlimab on day seven achieved a peak benefit of 82% lower mortality, the company said.
CytoDyn said that the effects diminished from day 14 to day 21 and from day 21 to day 28, as the mortality rate decreased to 50% and 31%, respectively, which the company attributed to patients not receiving leronlimab after day 7.
Price Action: CYDY shares are down 6.86% at $1.9 during the market session on the last check Tuesday.